“Targeted policies” aimed at improving the conditions for generic and biosimilar competition, removing barriers to market and increasing uptake and patient access have been put in motion by the European Commission as part of its Pharmaceutical Strategy for Europe announced today.
In a detailed document setting out its proposals, the Commission highlighted that “generic and biosimilar medicines provide a large...




